LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Self-citationEndogenous microRNA sponges: evidence and controversy
Thomson, D. W., & Dinger, M. E. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.20 · Cited by 2,185
Bianco, C., Normanno, N., Salomon, D. S., & Ciardiello, F. (1999) · Growth Factors · doi:10.1080/08977190410001723290 · Cited by 2,140
“miR-122 levels was observed, coupled with derepression of endogenous targets and absence of signifi cant associated toxicity [14].”
Garzon, R., Calin, G. A., & Croce, C. M. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.59.053006.104707 · Cited by 1,770
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
“An efficacy study conducted by Elmen et al on non-human primates (Elmen et al, 2008a), showed a dose-dependent sequestration of mature miR-122 and a long lasting decrease of total plasma cholesterol.”
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
“This leads to a higher efficiency and makes it possible to use shorter sequences to target the miRNA’s seed sequence (“tiny LNA”) (67, 205, 212).”
BackgroundMicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
“Likewise, subcutaneous delivery of the LNA miR-122 inhibitor effectively suppresses HCV replication in African green monkeys and is currently being tested in humans (Elmén et al., 2008; Lanford et al., 2010).”
BackgroundDi Leva, G., Garofalo, M., & Croce, C. M. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,672
“In vivo antisense-mediated inhibition of miR-122 is well tolerated in adult mice; it reduces serum cholesterol and leads to the induction of genes normally repressed in adult liver (81), suggesting that this miRNA is important for maintenance of the terminally differentiated hepatocyte gene expression program.”
BackgroundComprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites
Betel, D., Koppal, A., Agius, P., Sander, C., & Leslie, C. (2010) · Genome Biology · doi:10.1186/gb-2010-11-8-r90 · Cited by 1,592
“Rank correlations were computed between prediction scores and observed log expression changes for 17 test sets measuring mRNA expression changes following microRNA transfection in different cell lines and genetic backgrounds [21] (brown), five test sets measuring protein expression changes following microRNA transfect…”
MethodMicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
“A variety of chemical modifications can be made to increase the stability and potency of antagomirs, including 2’-O-methyl modified ribose sugars [14], 2’-O-methoxyethyl-modified ribose sugars [13] and addition of an extra 2’-O, 4’-C methylene bridge in the ribose sugar [362].”
BackgroundHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Lee, Y. S., & Dutta, A. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092222 · Cited by 1,505
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
“The simple systemic delivery of an unconjugated LNA anti-miR-122 (SPC3649, developed by Santaris Pharma) has also been shown to effectively antagonize liver-expressed miR-122 in non-human primate”
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Self-citationTherapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
“Thus far, most translational in vivo studies targeting miRNAs have aimed to inhibit miRNA function through the use of antisense reagents, such as antagomirs , locked nucleic acid (LNA) oligomers, and other modified oligonucleotides (Elmen et al., 2008; Esau et al., 2006; Krutzfeldt et al., 2005).”
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
“Two studies could show that miR-122 appears to suppress 100–200 genes in liver tissue as demonstrated in mice (Esau et al. 2006; Elmen et al. 2008a).”
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
The journal of clinical investigation
(1994) · Journal of the American Dietetic Association · doi:10.1016/0002-8223(94)92394-9 · Cited by 1,198
Pervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180
Cooper, T. A., Wan, L., & Dreyfuss, G. (2009) · Cell · doi:10.1016/j.cell.2009.02.011 · Cited by 1,159
“Delivery of LNA-modified oligonucleotides to block miR122 demonstrated both the loss of miR-122 and a functional consequence of lowered plasma cholesterol in mice and monkeys (Elmen et al., 2008).”
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
Fong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., Chow, A., O’Connor, S. T. F., Li, S., Chin, A. R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3094 · Cited by 1,118
MicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. (2012) · Nature reviews. Molecular cell biology · doi:10.1038/nrm3328 · Cited by 1,103
Jansson, M. D., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,099
“Studies on the inhibition of endogenous miRNA were pioneered by groups studying the liver-specificmiR-122 and its roles in controlling plasma cholesterol levels and facilitating Hepatitis C virus replication (Elmen et al., 2008a; Krutzfeldt et al., 2005; Lanford et al., 2010).”
BackgroundMicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
“(161) used intravenous injection of a 16-nt-long antisense, unconjugated, locked-nucleic-acid-modified oligonucleotide (LNA-antimiR), to deplete miR-122 in primates’ liver.”
BackgroundBracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., & Goodall, G. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1942 · Cited by 1,060
“In this regard, manipulation of microRNAs has recently been shown to be readily achievable in vivo and holds exciting promise for potential therapeutic applications involving the miR-200 family (42, 43).”
BackgroundTherapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
miR‐21: a small multi‐faceted RNA
Krichevsky, A. M., & Gabriely, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00556.x · Cited by 987
“Currently, synthetic chemically modified antisense oligonucleotides that can be delivered either systemically or locally [109–111], and particularly cholesterol-conjugated antagomirs, represent the most powerful tool for silencing a specific miRNA in vivo.”
BackgroundEmerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935
“LNA-modified miRNA antisense probes were previously shown to be capable of effectively sequestering miR-122 in vivo by forming duplexes with this miRNA (Elmén et al., 2008).”
BackgroundMicroRNAs: Synthesis, mechanism, function, and recent clinical trials
Wahid, F., Shehzad, A., Khan, T., & Kim, Y. Y. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.06.013 · Cited by 899
MicroRNAs and Cancer: Short RNAs Go a Long Way
Ventura, A., & Jacks, T. (2009) · Cell · doi:10.1016/j.cell.2009.02.005 · Cited by 891
“As increasingly effective pharmacological means to modulate miRNA activities are currently being developed (Elmen et al., 2008), identifying miRNAs that are essential for tumor maintenance or for metastasis might provide exciting new therapeutic opportunities.”
BackgroundProgress in corneal wound healing
Ljubimov, A. V., & Saghizadeh, M. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.002 · Cited by 872
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript cholesterol by targeting simultaneously a number of cholesterol biosynthesis genes in mice and non-human primates (Elmen et al., 2008a, 2008b; Krützfeldt et al., 2005).”
BackgroundMicroRNA functions in stress responses
Leung, A. K. L., & Sharp, P. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.027 · Cited by 865
“Anantagomir againstmiR-122hasbeendemonstrated in animals to lower hepatitis C virus replication levels and cholesterol levels (Elmen et al., 2008; Krutzfeldt et al., 2005; Lanford et al., 2010).”
MicroRNA silencing for cancer therapy targeted to the tumour microenvironment
Cheng, C. J., Bahal, R., Babar, I. A., Pincus, Z., Barrera, F., Liu, C., Svoronos, A., Braddock, D. T., Glazer, P. M., Engelman, D. M., et al. (2015) · Nature · doi:10.1038/nature13905 · Cited by 823
The Mammalian Ovary from Genesis to Revelation
Edson, M. A., Nagaraja, A. K., & Matzuk, M. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0012 · Cited by 820
miR-155 gene: A typical multifunctional microRNA
Faraoni, I., Antonetti, F. R., Cardone, J., & Bonmassar, E. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.02.013 · Cited by 815
Ueda, T., Volinia, S., Okumura, H., Shimizu, M., Taccioli, C., Rossi, S., Alder, H., Liu, C.-G., Oue, N., Yasui, W., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70343-2 · Cited by 797
MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes
Jayawardena, T. M., Egemnazarov, B., Finch, E. A., Zhang, L., Payne, J. A., Pandya, K., Zhang, Z., Rosenberg, P., Mirotsou, M., & Dzau, V. J. (2012) · Circulation Research · doi:10.1161/circresaha.112.269035 · Cited by 775
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver
Hsu, S.-H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., Yu, L., Bai, S., La Perle, K., Chivukula, R. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63539 · Cited by 774
“8 × 10–4) without significantly altering triglyceride (TG) levels, corroborating previous observations in mice (2, 3) and primates (5, 16) depleted of miR-122 by administration of antisense oligonucleotides.”
Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
Ma, L., Reinhardt, F., Pan, E., Soutschek, J., Bhat, B., Marcusson, E. G., Teruya-Feldstein, J., Bell, G. W., & Weinberg, R. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1618 · Cited by 772
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743
Coulouarn, C., Factor, V. M., Andersen, J. B., Durkin, M. E., & Thorgeirsson, S. S. (2009) · Oncogene · doi:10.1038/onc.2009.211 · Cited by 733
“Given that the modulation of miR-122 expression became a reality in animal models (Czech, 2006; Elmen et al., 2008), our study provides a rationale for the classification and development of novel therapy for human HCC.”
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine
Chakraborty, C., Sharma, A. R., Sharma, G., Doss, C. G. P., & Lee, S.-S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.06.005 · Cited by 731
“In other study, Elmén et al.(76,77) used single LNA-anti-miR i.”
BackgroundMethodInfluentialKojima, K., Takata, A., Vadnais, C., Otsuka, M., Yoshikawa, T., Akanuma, M., Kondo, Y., Kang, Y. J., Kishikawa, T., Kato, N., et al. (2011) · Nature Communications · doi:10.1038/ncomms1345 · Cited by 118
“In situ hybridization to assess miR122 and miR214 The expression of miR122 and miR214 in mouse liver and human HCC tissues was examined by in situ hybridizatio”
Farazi, T. A., Hoell, J. I., Morozov, P., & Tuschl, T. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-5590-1_1 · Cited by 693
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
“Many of these oligonucleotides are fully phosphorothioated, very often in conjunction with LNAs, such as those directed against microRNA (miR)-122 to protect against hepatitis C infection [98].”
Targeting noncoding RNAs in disease
Adams, B. D., Parsons, C., Walker, L., Zhang, W. C., & Slack, F. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci84424 · Cited by 673
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways
Schetter, A. J., Heegaard, N. H. H., & Harris, C. C. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp272 · Cited by 657
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Self-citationMicroRNA Regulation of Atherosclerosis
Feinberg, M. W., & Moore, K. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306300 · Cited by 627
“particularly in targeting miRNA expression in the liver (eg, miR-122 and miR-33).(13,26) Cholesterol analogs have been”
BackgroundDevelopment of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
“Furthermore, inhibition of miR-122 has been shown to lower both LDL cholesterol and HDL cholesterol levels mice and non-human primates (Elme´n et al , 2008b), which implies that miR-122 is not a good therapeutic target for reducing increased levels of LDL cholesterol in hypercholesterolemia.”
InfluentialSelf-citationMicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
MicroRNAs: History, Biogenesis, and Their Evolving Role in Animal Development and Disease
Bhaskaran, M., & Mohan, M. (2014) · Veterinary Pathology · doi:10.1177/0300985813502820 · Cited by 605
“In African green monkeys, mature miR-122 was effectively and stably silenced using intravenously administered LNA–anti-miRNA-122 with no adverse effects.(40) Many studies in this direction have yielded promising results.”
BackgroundTherapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E. (2011) · Circulation · doi:10.1161/circulationaha.111.030932 · Cited by 603
“Single-stranded oligonucleotides have been shown to be effective in inactivating miRNAs in vivo 17–21 and represent a potentially effective means of inactivating pathological miRNAs.”
InfluentialNucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)
Lächelt, U., & Wagner, E. (2015) · Chemical Reviews · doi:10.1021/cr5006793 · Cited by 600
MicroRNAs Add a New Dimension to Cardiovascular Disease
Small, E. M., Frost, R. J. A., & Olson, E. N. (2010) · Circulation · doi:10.1161/circulationaha.109.889048 · Cited by 599
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595
A transfer-RNA-derived small RNA regulates ribosome biogenesis
Kim, H. K., Fuchs, G., Wang, S., Wei, W., Zhang, Y., Park, H., Roy-Chaudhuri, B., Li, P., Xu, J., Chu, K., et al. (2017) · Nature · doi:10.1038/nature25005 · Cited by 574
“We identified and selected tsRNAs from expression screens in HeLa and HCT-116 cells and used locked nucleic acid/DNA-mixed anti-sense oligonucleotides (LNA/ASO mixmer) 15,16 to inhibit various transcripts (Fig.”
Self-citationTGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN
Kato, M., Putta, S., Wang, M., Yuan, H., Lanting, L., Nair, I., Gunn, A., Nakagawa, Y., Shimano, H., Todorov, I., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1897 · Cited by 573
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Self-citationExperimental strategies for microRNA target identification
Thomson, D. W., Bracken, C. P., & Goodall, G. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr330 · Cited by 544
“There are a variety of miRNA silencing chemistries including anti-miRs (47,48), antagomiRs (49), miRNA sponges (50) and TuD (tough decoy) constructs (51).”
BackgroundMa, X., Becker Buscaglia, L. E., Barker, J. R., & Li, Y. (2011) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjr007 · Cited by 542
“…that the development of new miRNA inhibition tools such as cholesterol conjugates (Krutzfeldt et al., 2005) and locked nucleic acids (LNAs) (Elmen et al., 2008) and the discovery of dysregulation and/or mutation at M ahidol U niversity, Faculty of M edicine, Siriraj H ospital on February…”
MicroRNA‐29, a key regulator of collagen expression in systemic sclerosis
Maurer, B., Stanczyk, J., Jüngel, A., Akhmetshina, A., Trenkmann, M., Brock, M., Kowal‐Bielecka, O., Gay, R. E., Michel, B. A., Distler, J. H. W., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27443 · Cited by 539
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Zhang, Y., Wang, Z., & Gemeinhart, R. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.015 · Cited by 535
“Further utilizing modifications at the 2′-oxygen, LNAs are RNA analogs with the ribose moiety chemically locked by a bridge connecting the 2′-oxygen and 4′-carbon in a RNA-mimicking N-type (C3′-endo) conformation [61].”
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Khan, A. A., Betel, D., Miller, M. L., Sander, C., Leslie, C. S., & Marks, D. S. (2009) · Nature Biotechnology · doi:10.1038/nbt.1543 · Cited by 534
“Therapeutic siRNAs have also been designed for potential treatment of cancer, including in melanoma, against VEGF-A/-C [42], and through antimiR-21 in glioma [38,43,44].”
van Rooij, E. (2011) · Circulation Research · doi:10.1161/circresaha.110.227496 · Cited by 534
Inhibition of miR-15 Protects Against Cardiac Ischemic Injury
Hullinger, T. G., Montgomery, R. L., Seto, A. G., Dickinson, B. A., Semus, H. M., Lynch, J. M., Dalby, C. M., Robinson, K., Stack, C., Latimer, P. A., et al. (2012) · Circulation Research · doi:10.1161/circresaha.111.244442 · Cited by 501
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
“administration of a locked nucleic acid-modified antisense miRNA in primates (44) supports the feasibility of in vivo targeting miRNAs in therapy of human diseases.”
BackgroundMicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy
Cho, W. C. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.12.014 · Cited by 486
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
“Various chemistries have been shown to be active as inhibitors of miRNA function, including PNA [67], LNA [65–68], 2′-O-Me [69], 2′-MOE [64], and morpholino [70].”
BackgroundMicroRNA history: Discovery, recent applications, and next frontiers
Almeida, M. I., Reis, R. M., & Calin, G. A. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.03.009 · Cited by 466
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects
Jimenez-Mateos, E. M., Engel, T., Merino-Serrais, P., McKiernan, R. C., Tanaka, K., Mouri, G., Sano, T., O'Tuathaigh, C., Waddington, J. L., Prenter, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2834 · Cited by 459
MicroRNA regulatory networks in human adipose tissue and obesity
Arner, P., & Kulyté, A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.25 · Cited by 457
Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153
Doxakis, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.086827 · Cited by 454
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
“) dosing of LNA-modifi ed oligonucleotides to African green monkeys (Elmen et al., 2008).”
microRNA Therapeutics in Cancer — An Emerging Concept
Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.017 · Cited by 453
“Another example of modified AMOs are the Locked Nucleic Acid (LNA) anti-miRs, in which an extra methylene bridge connecting the 2′-O atom and the 4′-C atom ‘locks’ the ribose ring in a C3′-endo or C2′-endo conformation (Vester and Wengel, 2004; Elmen et al., 2008).”
BackgroundDeveloping MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
MicroRNAs in Cardiovascular Disease
Barwari, T., Joshi, A., & Mayr, M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.945 · Cited by 445
“Unfortunately, initial optimism was dampened by subsequent studies that showed a simultaneous decrease in high-density lipoprotein cholesterol levels (57).”
BackgroundAn HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis
Hatziapostolou, M., Polytarchou, C., Aggelidou, E., Drakaki, A., Poultsides, G. A., Jaeger, S. A., Ogata, H., Karin, M., Struhl, K., Hadzopoulou-Cladaras, M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.043 · Cited by 445
“Previous studies have aimed to suppress microRNA expression in animal models through delivery of antagomirs or locked nucleic acid (LNA) oligomers (Elmén et al., 2008; Esau et al., 2006).”
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Bernardo, B. C., Gao, X.-M., Winbanks, C. E., Boey, E. J. H., Tham, Y. K., Kiriazis, H., Gregorevic, P., Obad, S., Kauppinen, S., Du, X.-J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206432109 · Cited by 429
“Modifications used to enhance the binding affinity of antimiRs to their cognate miRNAs and to facilitate cellular uptake for in vivo delivery include incorporation of 2′-O-methyl, 2′-O-methoxyethyl, locked nucleic acid (LNA), 3′ cholesterol conjugation (antagomiRs), and phosphorothioate backbone modification (3, 5, 7,…”
BackgroundMethodSelf-citationNon-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications
Wong, C.-M., Tsang, F. H.-C., & Ng, I. O.-L. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.169 · Cited by 424
Visone, R., & Croce, C. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080794 · Cited by 422
MicroRNAs As Novel Regulators of Angiogenesis
Suárez, Y., & Sessa, W. C. (2009) · Circulation Research · doi:10.1161/circresaha.108.191270 · Cited by 416
Pencheva, N., Tran, H., Buss, C., Huh, D., Drobnjak, M., Busam, K., & Tavazoie, S. F. (2012) · Cell · doi:10.1016/j.cell.2012.10.028 · Cited by 415
Liver-specific microRNA-122: Biogenesis and function
Jopling, C. (2012) · RNA Biology · doi:10.4161/rna.18827 · Cited by 415
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
Creemers, E. E., & Pinto, Y. M. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq308 · Cited by 403
“In this regard, silencing of the liver-specific miR-122 in monkeys recently resulted in a long-lasting lowering of plasma cholesterol levels.(85) A specific inhibitor of miR-122 is the first miRNA-targeted drug that has entered a human clinical trial, in patients infected with Hepatitis C.”
Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Tavolari, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4797 · Cited by 401
“Therefore, taking advantage of promising in vivo studies on miRNAs (7, 8), this class of molecules may represent a new kind of unconventional targeted treatment to be eventually associated with traditional approaches for HCC not amenable of curative therapies.”
Background
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.